Neurotech International Ltd. (AU:NTI)

ASX:NTI

NTI

Neurotech International

RESEARCH TOOLSreports

Want to see AU:NTI full AI Analyst Report?

Neurotech International (NTI) Price & Analysis

Q: What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.

Q: What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$15.81M.

Q: When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.

Q: How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Q: Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

Q: What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,317,741,700 shares outstanding.

Q: What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.

Q: Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

11 Followers

NTI Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.03

Previous CloseN/A

Volume11.09K

Average Volume (3M)768.84K

Market Cap

AU$15.81M

Enterprise ValueAU$5.80M

Total Cash (Recent Filing)AU$6.34M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding1,317,741,700

10 Day Avg. Volume770,041

30 Day Avg. Volume768,844

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.26

Price to Sales (P/S)6.36

P/FCF Ratio-1.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Minimal Leverage / Zero DebtHaving essentially zero debt gives the company durable solvency and strategic optionality: it can prioritize R&D or raise equity without immediate debt servicing headwinds. This improves resilience during multi-year clinical programs and reduces bankruptcy risk while outcomes are uncertain.

Focused R&D Business ModelA narrow, clinical-stage biotech model concentrates resources on high-value drug development rather than broad commercial operations. With a small team and targeted programs, success in trials can produce material value creation while keeping operating complexity and fixed-cost escalation lower than diversified healthcare peers.

FY2025 Revenue Rebound And High Gross MarginThe FY2025 revenue rebound and reported 100% gross margin indicate early commercial or licensing traction and a product mix that can scale without proportional COGS increases. If sustained and expanded, this supports margin improvement and levered operating leverage as fixed R&D costs are spread over higher sales.

Bears Say

Accelerating Cash BurnSteadily worsening free cash flow signals rising funding needs over the coming 2-6 months and beyond; clinical-stage programs are cash intensive. Without material EBITDA improvement or external financing, execution risk rises as capital shortfalls can delay trials or force dilutive funding rounds.

Shrinking And Volatile Equity BaseA sharply reduced equity base reflects accumulated losses and potential prior dilution, weakening the buffer against losses and constraining balance-sheet flexibility. Persistent reductions in equity increase dependency on external funding and elevate shareholder dilution risk during critical clinical development phases.

Deep And Persistent Operating LossesOperating costs far exceed current revenue scale, implying the business cannot self-fund development. Such negative margins suggest a long runway to breakeven even if revenue growth continues; sustained losses raise concerns about whether future commercial scale can be achieved without major strategy shifts.

Neurotech International News

Neurotech Director Options Expire Without Exercise

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International has reported a change in...

24d ago

NTI

Neurotech Options Lapse, Trimming Potential Future Dilution

An update from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has notified the market that...

24d ago

NTI

Maybank Securities Exits Substantial Holder Position in Neurotech International

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has disclosed that Maybank Securities...

29d ago

NTI

Neurotech Showcases Paediatric Neurology Drug NTI164 at Hong Kong Investment Summit

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International will present its lead cannabinoid-based...

1M ago

NTI

Neurotech Director Mark Davies Increases Indirect Shareholding

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has disclosed a change in director Mark...

2M ago

NTI

Neurotech clears secondary trading for new share issue

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has issued new fully paid...

2M ago

NTI

Neurotech International Seeks ASX Quotation for 21.4 Million New Shares

Neurotech International ( ($AU:NTI) ) just unveiled an announcement. Neurotech International Limited has applied for quotation on the...

2M ago

NTI

Neurotech to Highlight Paediatric Neurology Pipeline at NWR Virtual Healthcare Conference

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International, a clinical-stage biopharmaceutical company specialising in paediatric...

2M ago

NTI

Neurotech Flags Risks and Uncertainties in Neurodevelopmental Drug Strategy

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has outlined its current corporate...

2M ago

NTI

Neurotech Investors Back Capital Raisings and Director Participation at General Meeting

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has reported the results of its 12...

2M ago

NTI

NTI FAQ

What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.

What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$15.81M.

When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.

How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,317,741,700 shares outstanding.

What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Underperform

Fundamentals

Return on Equity

-87.19%

Trailing 12-Months

Asset Growth

5.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurotech International Ltd.

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.